Evidence map›Paper›PMID 21658613›Full record

ReviewBest practice & research. Clinical haematology2011

Host genetics in follicular lymphoma.

James R Cerhan

Abstract readReview
In one paragraph

Review in Best practice & research. Clinical haematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Epidemiology of Follicular Lymphoma.Hematology/oncology clinics of North America · 2020
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

James R CerhanDivision of Epidemiology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. cerhan.james@mayo.edu
Mayo Clinic · US

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
Molecular Epidemiology of NHL and CLLR01CA092153 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R · 2003 to 2012
$6.7M
Molecular Epidemiology of non-Hodgkin Lymphoma SurvivalR01CA129539 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R · 2009 to 2010
$1.2M
NCI NIH HHS P50 CA097274NCI NIH HHS P50 CA97274NCI NIH HHS R01 CA092153NCI NIH HHS R01 CA129539NCI NIH HHS R01 CA92153
6 · The paper itself

Abstract

The role of inherited (host) genetic susceptibility in the pathogenesis of follicular lymphoma (FL) is reviewed. First degree relatives of FL patients are at an increased risk of FL, suggesting a role for inherited factors. While there have been no linkage studies in FL families, candidate gene and genome-wide association studies have identified several risk loci which have been confirmed in independent studies. These include regions on 6p21.32-33 and TNF family members. Host genetics has also been hypothesized to influence treatment response, disease progression and overall survival. Early leads in FL prognosis include pathways that regulate immune function, antibody-dependent cellular cytotoxicity, chemotaxis, and one-carbon metabolism, although few of these associations have been independently confirmed. While the use of host genetics to identify individuals at high risk of FL or to predict FL treatment response and prognosis appears to be very promising, it is not yet ready for the clinic.

Indexed as

Genetic Predisposition to DiseaseChromosomes, Human, Pair 6Genome-Wide Association StudyHumansLymphoma, FollicularPolymorphism, Single NucleotidePrognosisRisk FactorsSurvival RateTumor Necrosis Factor-alphaTumor Necrosis Factor-alpha

Identifiers

PMID21658613
PMCPMC3112359
OpenAlexW1982731054

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.